These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33866938)

  • 21. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
    Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
    Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.
    Maio M; Amonkar MM; Norquist JM; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Wang R; Norwood K; Marabelle A
    Eur J Cancer; 2022 Jul; 169():188-197. PubMed ID: 35588692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
    Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
    Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
    Chu JN; Choi J; Ostvar S; Torchia JA; Reynolds KL; Tramontano A; Gainor JF; Chung DC; Clark JW; Hur C
    Cancer; 2019 Jan; 125(2):278-289. PubMed ID: 30343509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
    Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
    Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
    Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
    Front Public Health; 2022; 10():956792. PubMed ID: 36016894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    Pharmacoeconomics; 2017 Aug; 35(8):831-844. PubMed ID: 28620848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
    Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X
    Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
    Huang M; A Fasching P; Haiderali A; Xue W; Yang C; Pan W; Zhou ZY; Hu P; Chaudhuri M; Le Bailly De Tilleghem C; Cappoen N; O'Shaughnessy J
    Adv Ther; 2023 Mar; 40(3):1153-1170. PubMed ID: 36648737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
    Zhan M; Xu T; Zheng H; He Z
    Front Public Health; 2022; 10():790225. PubMed ID: 35309225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China.
    Zheng Z; Yang L; Xu S; Zhu H; Cai H
    Front Pharmacol; 2022; 13():944931. PubMed ID: 36249813
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
    Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.